PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Insights
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Insights
  • Our team
  • Join us

Beware of boilerplate: Practical lessons for patent drafting from G1/24 (Claim interpretation)

  • Sector: Uncategorized
  • 11th April 2025
 

Following the high profile hearing last month, we are now waiting for the written decision of the Enlarged Board of Appeal (EBA) in G 1/24. Readers can catch-up on the full background to the case here. There is also still plenty to discuss while we wait. 

G 1/24 relates to the question of how to interpret the claims of a patent, and whether the description of the patent may be used for this purpose. Most patent attorneys like nothing more than arguing about the meaning of words. What then could be better than an argument about how to argue about the meaning of words, as we may liberally paraphrase G 1/24. However, whilst this is all very exciting for patent attorneys, we are still left with the question of the practical implications of G 1/24? Even before the EBA issues its decision, there are some lessons to be learnt from the case on drafting the description of a patent.These lessons are even more important with the increased use of AI patent tools for patent drafting.

Beware of boilerplate

One key lesson from the case at the centre of G 1/24 can be summarised very succinctly. When drafting a patent, beware of overusing boilerplate language. 

The patent at issue in the referring decision to G 1/24 (T 0439/22) was a Philip Morris patent for a heated aerosol-generating article for use with an electrically-operated aerosol-generating device (e.g. a heat-not-burn e-cigarette), in which an “aerosol-forming substrate comprises a gathered sheet of aerosol-forming material” (e.g. a sheet of gathered tobacco). A key question for the novelty of the claim was whether the product disclosed by the prior art disclosed a “gathered” sheet of tobacco. The prior art disclosed a product comprising a tobacco sheet that “may be spirally wound”. The Board of Appeal in the case was convinced that a person skilled in the art would not normally consider the definition of a “gathered tobacco sheet” to include tobacco sheets that were spiralled. The skilled person, it was agreed, would normally understand a gathered tobacco sheet to be one that was “folded and convoluted”. 

However, critically, the description of the patent included the following definition: 

As used herein, the term ‘gathered’ denotes that the sheet of tobacco material is convoluted, folded, or otherwise compressed or constricted substantially transversely to the cylindrical axis of the rod.

For the Board of Appeal in the case, this broader definition of the term “gathered” encompassed the spiralled tobacco sheet disclosed by the prior art. In other words, if the description could be used to redefine terms of the art used in the claims, then the patentee had shot themselves in the foot with their overly broad definition. In the view of the Board of Appeal in the case, using the broadening definition provided by the description, the claimed invention lacked novelty. 

The case in T 0439/22 thus highlights the dangers of unnecessary boilerplate language. Given that the term “gathered” has an accepted definition within the field, why then does the term need to be defined in the description at all? If the patentee is intentionally trying to broaden the scope of protection offered by the claims to include sheets of tobacco not falling under the commonly accepted definition of “gathered”, then the claims would be the best place to do this. The patentee could simply have used different terminology in the claims. The use of the description to redefine words that are used in the claims creates a lack of clarity that is not conducive to legal certainty. As the case in G 1/24 illustrates, this lack of clarity may harm the patentee as well as third parties. 

In short, beyond all the nuanced legal debate, a key practical take-home message from G 1/24 is simply to avoid, as much as possible, unnecessary boilerplate that may undermine your carefully crafted claims. 

The importance of technical field

Arguably, the practical implications of G 1/24 for drafting practice vary according to the technical field. In the mechanical field of patent drafting, the definitions of words can be quite fluid and open to interpretation. It is often difficult in mechanical patents to interpret words without the context of the description. To interpret claim terminology such as for example, housing, member, plate, panel, and flange, it is generally necessary to understand what the purpose of these features are in the invention.

By contrast, in technically specialised fields such as biotech and software, terminology is often more clearly defined in the field. Terms such as cell, DNA, nucleic acid sequence, epitope, and chimeric antigen receptor have well-understood definitions. Of course, there will always be some scope for interpretation, but the definitions of such words are still far more delineated than the words often used in mechanical drafting. It is therefore no surprise that the referring case in G 1/24 was from the mechanical field. The point of contention in G 1/24 relates to a word (“gathered”) that on the face of it appears relatively non-technical and open to interpretation.

However, even within the field of tobacco products, the terminology used in patent claims will of often have well-understood definitions. This was in fact the case in T 0439/22, in which it was accepted that gathered would normally be understood by a skilled person to refer to the type of tobacco sheets manufactured on standard crimping machines and thus not encompass spiralled tobacco. The problem for the patentee was the non-technical definition of gathered provided in the application. Given that “gathered” is a well-understood term in the field, defining it in the specification was arguably unnecessary. 

A practical lesson from G 1/24 is thus to ensure that any definitions of technical terms provided in the specification which differ from their normal technical meaning are included with the full intention of redefining the term. As suggested above, the safest plan would be to define the invention clearly in the claim. 

Beware even more of AI generated boilerplate

The increased use of these tools in the industry also raises interesting questions so far as definitions are concerned. Many of the tools on offer will draft definitions for the description based on your claims. In my experience, without extensive user input and prompting these definitions are often highly unsuitable and are in many cases overly narrowing. Filling the specification with impressive sounding technical language defining terminology used in the claims may give the impression of a well-drafted patent, but this impression would be misleading. G 1/24 is a timely reminder that the description of a patent may be highly influential for how the scope of the claims is determined. AI patent drafting tools to automate a comprehensive glossary of terms based on the claims, should therefore be used with care. 

Final thoughts

Before even the Enlarged Board of Appeal issues its written decision in G 1/24, there are already a number of lessons for patent drafting that can be taken from the issues at stake in the case. Wherever the Enlarged Board of Appeal lands on description-based claim interpretation, the fundamental principle of patent drafting remains the same. If you want the scope of the claims to be clear, the best place to ensure this is in claims. As the arrival of AI drafting tools reminds us, there is no substitute for careful, deliberate drafting of both claims and description.

Related insights...

Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

  • 9th May 2025
In recent years, Novo Nordisk’s weight loss drug semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, has become a pharmaceutical phenomenon. As with most successful pharmaceutical products, the remarkable success of semaglutide means we can also expect some high profile IP disputes. In jurisdictions lacking provisions for patent term extension, semaglutide is expected to face generic challenge…

The plausibility of diagnostic inventions: No data, no patent (T 0589/22)

  • 30th April 2025
In T 0589/22, the Board of Appeal revoked a patent for an in vitro diagnostic method on the basis that the claimed diagnostic effect was not rendered plausible. According to the Board of Appeal’s interpretation of the claims, none of the examples in the patent related to the population of subjects defined by the claims.…

AlphaFold: From Nobel Prize to drug-discovery gold mine?

  • 29th April 2025
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst large language models such as ChatGPT can write poems and make pretty pictures, AlphaFold has the potential to dramatically impact the life-and-death world of drug discovery. AlphaFold represents truly ground-breaking science for which its…

G 2/21 applied to software inventions (T 0687/22)

  • 29th April 2025
The EPO Board of Appeal decision in T 0687/22 confirms beyond doubt the relevance of G 2/21 to software inventions. The decision in T 0687/22 links the case law from G 1/19 and G 2/21 to highlight the importance of establishing a credible technical effect of software invention. The Patentee in the case made several attempts to formulate an objective technical problem solved by the invention based…

Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22)

  • 29th April 2025
IP strategy for cell therapy also has unique challenges. The patent at issue in T 1259/22, although relatively old (expiring August 2024 with SPCs), nonetheless highlights some of the key challenges for cell therapy IP strategy.

Beyond the process: Securing robust IP protection for cell therapies

  • 29th April 2025
Unlike traditional pharmaceuticals, these “living medicines” present unique IP challenges that can make or break a biotech’s future…

Securing market protection for cell therapies: Patents versus regulatory exclusivity

  • 29th April 2025
Conventional approaches to LoE fail to capture the complex reality of cell therapy products. IP strategy for cell therapy needs to be adapted to take account of these realities.

Too broad, too early? AI platform for cell analysis found to lack technical character and sufficiency (T 0660/22, Cell analysis/NIKON)

  • 29th April 2025
This decision highlights some of the challenges associated with trying to broadly protect software-based platform technology for biological research.

Use versus process patents: Implications for novelty and scope (T 1913/21)

  • 9th April 2025
The recent decision T 1913/21 highlights a crucial differentiation between second non-medical use claims and process claims. The Board of Appeal found that, according to the established case law, claims in which the technical effect of the invention occurs only as part of a process for producing a product, must be regarded as a process claim and…

Excluding a technical feature is not inventive without evidence of a technical effect (T 1865/22)

  • 21st March 2025
The recent Board of Appeal decision in T 1865/22 considered the inventive step of a composition where the only distinguishing feature was a lower concentration of a component compared to the closest prior art. The prior art taught that higher concentrations of this component were advantageous. The Board of Appeal found that simply excluding a technical feature disclosed…
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Contact Us